Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Cardiovascular Disease-Hypercholesterolemia

Request The Product List ofHypercholesterolemia Hypercholesterolemia

Cholesterol travels through the blood on proteins called “lipoproteins.” Two types of lipoproteins carry cholesterol throughout the body:

~ LDL (low-density lipoprotein), sometimes called “bad” cholesterol, makes up most of your body’s cholesterol. High levels of LDL cholesterol raise your risk for heart disease and stroke.

~HDL (high-density lipoprotein), or “good” cholesterol, absorbs cholesterol and carries it back to the liver. The liver then flushes it from the body. High levels of HDL cholesterol can lower your risk for heart disease and stroke.

When your body has too much LDL cholesterol, the LDL cholesterol can build up on the walls of your blood vessels. This buildup is called “plaque.” As your blood vessels build up plaque over time, the insides of the vessels narrow. This narrowing blocks blood flow to and from your heart and other organs. When blood flow to the heart is blocked, it can cause angina (chest pain) or a heart attack.

Cat. No. Product Name CAS No. Information
H6811

PF-06815345

 		1900686-46-5

PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay; PF-06815345is identified after optimization of the prodrug moiety to maximize intestinal stability achieving liver targeting of the active compound after prodrug turnover by carboxylesterase (CES1).

H6743

TMP-153

 		128831-46-9

TMP-153 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor with IC50 of 5-10 nM for the hepatic and intestinal ACAT from various animals; inhibits cholesterol esterification both in human colonic adenocarcinoma cells, LS180, and in human hepatoma cells, HepG2 (IC50 = 150 nM and 330 nM, respectively); inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters.
H5897

Fenofibrate

 		49562-28-9

A PPARα agonist that exhibits EC50 of 18 and 30 uM for murine and human PPARα, respectively, in a transactivation assay; reduces both LDL and VLDL levels, as well as increasing HDL levels and reduces triglyceride levels; mainly used to reduce cholesterol levels in people at risk of cardiovascular disease.
H5892

Choline Fenofibrate

 		856676-23-8

A PPARα agonist used for treatment of hyperlipidemia; increases SHP gene expression in cultured liver cells and in the normal and diabetic mouse liver by activating AMPK signaling pathway.
H5840

Ezetimibe

 		163222-33-1

A potent Niemann-Pick C1-Like 1 (NPC1L1) cholesterol absorption receptor inhibitor that inhibits sterol absorption without affecting the absorption of other molecules; significantly reduces plasma levels of total and low density lipoprotein cholesterol (LDL-C) both in vitro and in vivo; also is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis; increases autophagic flux, improves hepatic steatosis in obese and diabetic rats.
H4281

Lopixibat chloride

 		228113-66-4

Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).
H2198

Gemcabene calcium

 		209789-08-2

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP; down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism, inhibits IL-6 plus IL-1β-induced CRP production in a concentration-dependent manner in human hepatoma cells, reaching 70% inhibition at 2 mM; lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), attenuates osteoarthritis and pain in animal models of arthritis and Pain.
H2197

Gemcabene

 		183293-82-5

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP; down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism, inhibits IL-6 plus IL-1β-induced CRP production in a concentration-dependent manner in human hepatoma cells, reaching 70% inhibition at 2 mM; lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), attenuates osteoarthritis and pain in animal models of arthritis and Pain.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1